Lataa...
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
BACKGROUND: Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse cardiac events (MACE) in patients with cardiovascular disease (CVD) by 44% and in diabetic CVD patients by 57% on top of statins. A ph...
Tallennettuna:
| Julkaisussa: | Clin Epigenetics |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6626370/ https://ncbi.nlm.nih.gov/pubmed/31300040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0696-z |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|